The neurotechnology sector has seen a new entrant with the launch of Bridge Neurotech. The company aims to develop a wearable brain-computer interface (BCI) that relies on ultrasound technology rather than traditional electrical sensors. This approach is intended to allow for non-invasive neural monitoring and interaction.

Bridge Neurotech enters a space that is currently gaining significant attention from high-profile investors and tech leaders. Among its primary rivals is Merge Labs, a venture backed by OpenAI CEO Sam Altman. While specific technical specifications and clinical timelines for Bridge Neurotech’s device remain limited, the company’s entry highlights the ongoing race to create consumer-facing or medical-grade BCI hardware that does not require surgical implantation.

The competitive landscape for BCIs is currently divided between companies focusing on invasive implants, such as Neuralink, and those pursuing non-invasive wearables. Bridge Neurotech’s focus on ultrasound places it in a niche category of non-invasive research, aiming to bypass the limitations of current EEG-based wearables. Industry analysts are watching to see how the company differentiates its ultrasound-based signal processing from the established methods used by Altman’s Merge Labs and other competitors in the space.